Anzeige
Meldung des Tages: Revolutionäre Entwicklung im Megatrend – Der KI-Durchbruch für Pflege und Sicherheit!

Sandoz Group Aktie News

Aktie
WKN:  A3ETYB ISIN:  CH1243598427 US-Symbol:  SDZXF Branche:  Pharmazeutika Land:  Schweiz
60,62 CHF
+0,2 CHF
+0,33%
66,090 € 12:22:36 Uhr
Depot/Watchlist
Marktkapitalisierung *
27,76 Mrd. €
Streubesitz
46,54%
KGV
-
Dividende
0,60 CHF
Dividendenrendite
1,04%
neu: Nachhaltigkeits-Score
57 %
Index-Zuordnung
-
Weiter aufwärts? Long handeln - Jetzt mit Hebel 8,86: MM97VX
Werbung

Sandoz Group News

21.05.25 - GlobeNewswire
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars
MEDIA RELEASE
30.04.25 - GlobeNewswire
Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
29.04.25 - GlobeNewswire
Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications
MEDIA RELEASE
15.04.25 - GlobeNewswire
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
All proposals of Board of Directors approved Gilbert Ghostine re-​elected as Chairman of Board of Directors; all other Board members standing for re-​election confirmed Dividend of ...
14.04.25 - GlobeNewswire
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” ...
14.04.25 - GlobeNewswire
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
31.03.25 - GlobeNewswire
Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility
MEDIA RELEASE NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN
12.03.25 - wallstreetONLINE Redaktion
Novo Nordisk vs. Hikma: Novo Nordisk: Wer macht das Rennen? – Das Original oder Generika?
Semaglutid heißt der Wunderstoff, der hinter Ozempic und Wegovy von Novo Nordisk steckt. In einigen Ländern läuft 2026 der Patentschutz für Semaglutid aus. Wie schwer wird das ...
05.03.25 - GlobeNewswire
Sandoz reports strong FY 2024 results and Q4 2024 sales
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
24.02.25 - GlobeNewswire
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

Newssuche

Videos

newspaper
03.02.26
2026 02 03 17 34 Trendjumper Einführung
Zunächst inormieren wir unsere Stammkunden bezüglich des bevorstehenden Seminars und bieten für ... Mehr »